



## **Blueprint Medicines Appoints Charles A. Rowland, Jr. to its Board of Directors**

CAMBRIDGE, Mass., March 23, 2015 – Blueprint Medicines today announced the appointment of Charles A. Rowland Jr., CPA, to its Board of Directors. Mr. Rowland brings more than 30 years of experience in biopharmaceutical financial management and strategic business operations.

“With his extensive leadership and financial management experience, Charlie promises to be a tremendous asset to Blueprint as we advance simultaneously our two lead programs into clinical development,” said Jeffrey Albers, Chief Executive Officer of Blueprint Medicines. “Charlie has a proven track record of building high-value companies through strategic investment in research and development and smart financial management.”

Mr. Rowland most recently served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, a global biopharmaceutical company with \$500 million in revenues, until the company was acquired by Shire plc in January 2014. In this role, he oversaw all aspects of finance, including financial analysis and reporting, tax, treasury and investor relations, as well as strategic business planning and information technology. Before joining ViroPharma in 2008, Mr. Rowland was Executive Vice President and CFO, as well as interim Co-Chief Executive Officer, for Endo Pharmaceuticals, a specialty pharmaceutical company with \$1.3 billion in revenues. He previously held finance positions of increasing responsibility at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia Corp., Novartis AG and Bristol-Myers Squibb Co. Mr. Rowland also serves as a director and chair of the audit committees of Aurinia Pharmaceuticals, BIND Therapeutics, Vitae Pharmaceuticals and Nabriva Therapeutics, AG. He holds an M.B.A. from Rutgers’s University and a B.S. from Saint Joseph’s University.

“I look forward to working with the leadership team and board of Blueprint Medicines to advance their mission to discover, develop and deliver genomically defined medicines to patients in need,” said Mr. Rowland.

### **About Blueprint Medicines**

Blueprint Medicines makes kinase drugs to treat patients with genomically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer.

**CONTACT:**

Investor Relations:  
Beth DeGiaccio  
Stern Investor Relations, Inc.  
212-362-1200  
[beth@sternir.com](mailto:beth@sternir.com)

Media Relations:  
Beth Keshishian  
inVentiv Health PR  
212-229-8417  
[beth.keshishian@inventivhealth.com](mailto:beth.keshishian@inventivhealth.com)